After years of limited progress, COPD drug development is entering a pivotal moment. Recent milestones, including Sanofi's approval of the first biologic therapy, renewed Big Pharma engagement, and multi‑billion‑dollar deals, have reignited scientific, commercial, and investor interest in a disease area long viewed as high risk and high attrition. At the same time, advances in disease biology, translational science, and clinical development tools are creating new opportunities to succeed where previous approaches failed.
The COPD Drug Development Summit brings the industry together at this inflection point. This inaugural, industry‑led meeting convenes leaders from discovery through late‑stage development to explore how emerging modalities, smarter trial design, and more precise endpoints can unlock the next generation of COPD therapies. Built for biotech and pharmaceutical decision‑makers, the event focuses on practical strategies to reduce development risk, accelerate clinical proof‑of‑concept, and deliver meaningful benefit to heterogeneous COPD patient populations.
Join 65+ senior experts from leading and emerging organisations, including Johnson & Johnson, Sanofi, AstraZeneca, Merck, Ethris, Generate Biomedicines, and Connect Biopharma, for a highly focused forum combining scientific insight, case studies, and networking. With momentum returning to the space, this is a critical opportunity to align on what it will take to translate renewed investment into approved, disease‑modifying treatments for COPD.